Skip to main content

Table 1 In vitro activity of 7 aminoglycosides against 300 carbapenem-non susceptible K. pneumoniae in regards to carbapenemase production

From: Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance

Antimicrobial agent

MIC (mg/L)

Clinical breakpoint (mg/L)

% Susceptible

Range

MIC50

MIC90

EUCAST

CLSI

EUCAST

CLSI

All (n = 300)

 Plazomicin

0.125 - > 256

0.5

4

N/A

N/A

87.00% a

 Amikacin

1- > 256

32

128

≤8

≤16

18.00%

31.33%

 Gentamicin

0.25- > 256

4

> 256

≤2

≤4

43.00%

61.33%

 Tobramycin

0.25- > 256

32

256

≤2

≤4

8.67%

11.00%

 Netilmicin

0.25- > 256

128

> 256

≤2

≤8

9.00%

13.00%

 Neomycin

0.25- > 256

16

> 256

≤8b

N/A

43.67% a

N/A

 Apramycin

1-128

8

16

≤8c

N/A

86.67% c

KPC (n = 201)d

 Plazomicin

0.125 - > 256

1

4

N/A

N/A

84.58% a

 Amikacin

1- > 256

32

128

≤8

≤16

17.91%

31.34%

 Gentamicin

0.25- > 256

4

64

≤2

≤4

48.76%

71.14%

 Tobramycin

0.25- > 256

32

256

≤2

≤4

11.94%

14.93%

 Netilmicin

0.25- > 256

128

> 256

≤2

≤8

11.94%

16.92%

 Neomycin

0.5- > 256

32

> 256

≤8b

N/A

31.34% b

N/A

 Apramycin

1-128

4

16

≤8c

N/A

86.57% c

NDM (n = 52)e

 Plazomicin

0.125 - 2

0.5

1

N/A

N/A

100.00% a

 Amikacin

8-256

32

64

≤8

≤16

17.31%

44.23%

 Gentamicin

1- > 256

64

> 256

≤2

≤4

28.85%

36.54%

 Tobramycin

16- > 256

32

128

≤2

≤4

0.00%

0.00%

 Netilmicin

8- > 256

128

> 256

≤2

≤8

0.00%

1.92%

 Neomycin

1-32

2

8

≤8b

N/A

94.23% b

N/A

 Apramycin

2-32

4

8

≤8c

N/A

94.23% c

VIM (n = 21)

 Plazomicin

0.125 - > 256

1

> 256

N/A

N/A

71.43% a

 Amikacin

1- > 256

32

> 256

≤8

≤16

19.05%

42.86%

 Gentamicin

1- > 256

128

> 256

≤2

≤4

38.10%

42.86%

 Tobramycin

4- > 256

32

> 256

≤2

≤4

0.00%

4.76%

 Netilmicin

0.25- > 256

64

> 256

≤2

≤8

0.00%

0.00%

 Neomycin

0.5- > 256

32

> 256

≤8b

N/A

33.33% b

N/A

 Apramycin

2-64

4

16

≤8c

N/A

80.95% c

OXA-48 (n = 12)

 Plazomicin

0.125 - 4

0.5

2

N/A

N/A

91.67% a

 Amikacin

2-64

16

32

≤8

≤16

33.33%

58.33%

 Gentamicin

1-256

128

256

≤2

≤4

16.67%

16.67%

 Tobramycin

0.5-64

64

64

≤2

≤4

16.67%

16.67%

 Netilmicin

0.5-256

128

256

≤2

≤8

16.67%

16.67%

 Neomycin

0.25-256

2

16

≤8b

N/A

83.33% b

N/A

 Apramycin

4-8

8

8

≤8c

N/A

100.00% c

KPC and VIM (n = 14)

 Plazomicin

0.25 - 2

1

2

N/A

N/A

92.86% a

 Amikacin

4- > 256

64

256

≤8

≤16

7.14%

28.57%

 Gentamicin

1-64

4

8

≤2

≤4

42.86%

78.57%

 Tobramycin

8- > 256

32

128

≤2

≤4

0.00%

0.00%

 Netilmicin

4- > 256

128

> 256

≤2

≤8

0.00%

7.14%

 Neomycin

0.5- > 256

> 256

> 256

≤8b

N/A

14.29% b

N/A

 Apramycin

2-32

8

32

≤8c

N/A

57.14% c

  1. N/A, not available (breakpoints have not been established)
  2. a For plazomicin, the breakpoint recently approved by the FDA was used
  3. b For neomycin, EUCAST epidemiological cut-off values (ECOFFs) for E.coli were used
  4. c For apramycin, epidemiological breakpoints from the European Food Safety Authority (EFSA) were used
  5. d One isolate co-producing KPC and OXA-48-like is included
  6. e Two isolates co-producing NDM and OXA-48-like are included
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us